BioSpace News Archive

Rite Aid (NYSE: RAD) announced today that NARCAN® Nasal Spray, a medication used to reverse the effects of an opioid overdose, is available at all locations nationwide, including Bartell Drugs in the Pacific Northwest.

Senseonics Holdings, Inc., a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes, announced that it has entered into a $50 million loan facility with Hercules Capital, Inc.

Day One Biopharmaceuticals today announced the recently completed submission of the rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).

Avertix Medical, Inc. today announces that Company management will participate in two investor conferences in the month of September 2023.

Centogene N.V. today announced that CENTOGENE CEO Kim Stratton will present in the virtual track at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

Cytrellis Biosystems , today announced members of the Cytrellis leadership team will participate at the following conferences and events this September.

BioMarin Pharmaceutical Inc. will update the investor community on the company’s research and development portfolio, including early-stage product candidates and new indication opportunities with VOXZOGO and ROCTAVIAN.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced the expansion of its patent portfolio following the issuance of a Canadian patent for its Histone Deacetylase (HDAC) inhibitor platform technology titled “Dual Function Molecules for Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated (ATM) Activation and Methods of Use Thereof.”

NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that its Chief Medical Officer, Dr. Daniel Mikol, will present at the 2023 International Spinal Research Trust Network Meeting being held September 14-16 in London, UK.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced the peer-reviewed publication in Annals of Oncology* of the randomized Phase 3 clinical trial (Atalante-1**) on T-cell epitope cancer vaccine Tedopi® in HLA-A2 positive patients with advanced or metastatic NSCLC in monotherapy in third line NSCLC with secondary resistance to immune checkpoint inhibitors (ICI).